Literature DB >> 9533474

Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.

M E Evans1, W B Titlow.   

Abstract

Seventeen methicillin-resistant Staphylococcus aureus (MRSA) with unique genotypes were examined to determine if resistance occurs more frequently with ciprofloxacin or levofloxacin. The mean single-step resistance rate to 4 x MIC of ciprofloxacin was 1.05 x 10(-5) (range <4.82 x 10[-11] to 5.06 x 10[-5]), and that to levofloxacin was 4.03 x 10(-6) (range <3.57 x 10[-13] to 4.10 x 10[-5]) (P < 0.05). When serially passaged, the mean MICs of ciprofloxacin and levofloxacin increased 3.0 +/- 1.5-fold and 1.8 +/- 1.4-fold, respectively (P < 0.05). Only four strains became resistant to levofloxacin, but eight became resistant to ciprofloxacin (P < 0.05). Ciprofloxacin selects resistant MRSA more frequently than levofloxacin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533474     DOI: 10.1093/jac/41.2.285

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  The prevention of antibiotic resistance during treatment.

Authors:  J D Williams; A M Sefton
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.

Authors:  H F Chambers; Q Xiang; L L Chow; C Hackbarth
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Utilizing Pharmacy Records to Assess Antibiotic Prescribing Patterns on the Incidence of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections in Children.

Authors:  Peter N Johnson; Robert P Rapp; Christopher T Nelson; J S Butler; Sue Overman; Robert J Kuhn
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

4.  Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.

Authors:  D N Gilbert; S J Kohlhepp; K A Slama; G Grunkemeier; G Lewis; R J Dworkin; S E Slaughter; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Philip Chung; Patrick J McNamara; William B Titlow; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 7.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 8.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.